Community Acquired Pneumonia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Community Acquired Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions.
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
The Community Acquired Pneumonia drugs in development market research report provide comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Community Acquired Pneumonia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Community Acquired Pneumonia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Community Acquired Pneumonia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Community Acquired Pneumonia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AimMax Therapeutics IncAptarion Biotech AG
Basilea Pharmaceutica Ltd
Biotest AG
Capital Medical University
Changchun Haiyue Pharmaceutical Co Ltd
Clarametyx Biosciences Inc
Dompe Farmaceutici SpA
Eagle Pharmaceuticals Inc
Everest Medicines Ltd
Faron Pharmaceuticals Oy
FUJIFILM Toyama Chemical Co Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
ioGenetics Inc
Iterum Therapeutics Plc
KBP Biosciences Co Ltd
Korea Pharma Co Ltd
Melinta Therapeutics LLC
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
Senhwa Biosciences Inc
Shanghai SIMR Biotech Co Ltd
Sinovant Sciences HK Ltd
Swedish Orphan Biovitrum AB
TaiGen Biotechnology Co Ltd
Wockhardt Ltd
Zai Lab Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Community Acquired Pneumonia reports